Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Sulfasalazine for Oral Lichen Planus
NCT06060301Phase 3Active, not recruiting
- Sponsor
- Cairo University
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 5-aminosalicylic acid + sulphasalazine in oral lichen planus (OLP) (2 arms), sponsored by Cairo University. Primary endpoints: Numerical Analog Scale at 4 weeks and Sign scoring scale of Thongprasom at 4 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on NCT06060301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060301.